Fulcrum Therapeutics Appoints Biotech Executive Bryan Stuart as Chief Operating Officer

January 3, 2019

New COO brings extensive leadership and strategic expertise in rare disease

Cambridge, Mass. – January 3, 2019 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the appointment of Bryan E. Stuart as chief operating officer.

“Our primary goal at Fulcrum is to improve the lives of patients and families impacted by rare diseases, and Bryan’s leadership skills and track record will serve us well as we move forward,” said Robert J. Gould, Ph.D., Fulcrum’s president and chief executive officer. “I am glad to have his insight and experience as we further our efforts to develop disease-modifying therapies for patients who currently have none.”

“I am drawn to Fulcrum’s cutting-edge approach to rare disease research and development and am eager to work alongside Robert and the team as they continue to develop life-changing treatments for muscular dystrophies, sickle cell disease and other devastating disorders,” Stuart said. “Fulcrum has made significant progress advancing their rare disease pipeline, and I am excited to join at a pivotal time in the company’s growth.”

Stuart brings more than 20 years of leadership, strategic and operational experience to Fulcrum. He most recently served as president and CEO of Yarra Theraputics, a subsidiary of Array Biopharma, focused on developing therapeutics for genetically defined rare diseases. Previously he was president, then CEO of Kastle Therapeutics, a biopharma company focused on rare disease. He also served as chief business officer of Civitas Therapeutics (acquired by Acorda) which developed Inbrija® to treat Parkinson’s Disease. Stuart previously led business development and corporate strategy for both EKR Therapeutics (acquired by Cheisi) and Ovation Pharmaceuticals (acquired by Lundbeck A/S), a company focused on orphan CNS disorders. Stuart began his career as a healthcare investment banker at William Blair & Company. He holds an MBA from the Kellogg School at Northwestern University and a B.S. with high honors from the University of Illinois.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., has raised $135 million from two rounds of funding. Investors include Foresite Capital, Fidelity Management and Research Company, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32, NS Investments, entities affiliated with Leerink Partners and undisclosed institutional investors, as well as founding investor Third Rock Ventures. Fulcrum was launched in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.


Stephanie Simon
Ten Bridge Communications
[email protected]